Following microscopic inspection, the 134 cases were assigned to one of the four pathological phenotypes according to the varying forms and distribution of Aβ deposition (as SP and/or CAA) within frontal, temporal and occipital lobes, and coded accordingly Ceritinib in vivo (see methods for criteria) (Figure 1). However, there was often heterogeneity in phenotypic presentation across the three regions in individual cases. In some cases, all three regions showed

a similar histological phenotype, whereas in others there were regional variations with the frontal and temporal cortex closely resembling each other histologically though being dissimilar to occipital cortex, nearly always with respect to the presence/distribution of CAA. Hence, 35 cases (coded 111) showed type 1 pathology within all three regions (that is, Aβ deposition predominantly as SP with or without CAA, Sunitinib manufacturer and involving only superficial (leptomeningeal) blood vessels) (red in Figure 2). Sixty-eight cases (coded 112, 122, 212 or 222) showed type 2 pathology with Aβ deposition as SP and CAA in leptomeningeal and deeper intracortical vessels,

in the occipital lobe: dyshoric change was often evident surrounding affected vessels (green in Figure 2). Sometimes, similar changes were also seen in frontal but not temporal cortex (where type 1 change was present, and coded 212 or 122 respectively), or type 1 changes were only seen in both regions (and coded 112). Twenty cases showed type 3 pathology in all three regions (and coded 333) with robust CAA predominantly within capillaries in the occipital lobe, and leptomeningeal and/or intracortical CAA in frontal and/or temporal region (and coded 113, 123, 213, 223 or 323) (blue in Figure 2). In these cases, within occipital lobe SP were absent or relatively few, though were usually much more numerous in frontal and temporal lobes. Four cases (coded 214,

224 or 444) showed type 4 pathology with a predominant CAA phenotype, where Aβ was heavily deposited in the leptomeningeal and cortical vessels, but not capillaries, within occipital lobe (and sometimes also in frontal and temporal below lobes): dyshoric change was always evident surrounding the vessels. Aβ deposition, as SP, in occipital lobe was absent or infrequent (orange in Figure 2). For group comparisons, cases were pooled according to the type of histological presentation within the occipital lobe, irrespective of whether changes in frontal and temporal lobe always followed suit. Nonetheless, there were seven cases (coded 121, 211 or 221) which formed an ‘outlier’ group within type 2 pathology (purple in Figure 2). These were differentiated from the other cases with type 2 pathology by virtue of the fact that there was intracortical CAA in frontal and/or temporal cortex but, in contrast to the other cases in that group, these were without occipital involvement.